Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38394466)

  • 21. Comprehensive Analysis of R-Spondin Fusions and RNF43 Mutations Implicate Novel Therapeutic Options in Colorectal Cancer.
    Seeber A; Battaglin F; Zimmer K; Kocher F; Baca Y; Xiu J; Spizzo G; Novotny-Diermayr V; Rieder D; Puccini A; Swensen J; Ellis M; Goldberg RM; Grothey A; Shields AF; Marshall JL; Weinberg BA; Sackstein PE; Lim KH; Tan GS; Nabhan C; Korn WM; Amann A; Trajanoski Z; Berger MD; Lou E; Wolf D; Lenz HJ
    Clin Cancer Res; 2022 May; 28(9):1863-1870. PubMed ID: 35254413
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased cancer predisposition in family members of colorectal cancer patients harboring the p.V600E BRAF mutation: a population-based study.
    Wish TA; Hyde AJ; Parfrey PS; Green JS; Younghusband HB; Simms MI; Fontaine DG; Dicks EL; Stuckless SN; Gallinger S; McLaughlin JR; Woods MO; Green RC
    Cancer Epidemiol Biomarkers Prev; 2010 Jul; 19(7):1831-9. PubMed ID: 20570909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RNF43 is associated with genomic features and clinical outcome in BRAF mutant colorectal cancer.
    Shang P; Lu J; Song F; Zhao Y; Hong W; He Y; Shen W; Geng L
    Front Oncol; 2023; 13():1119587. PubMed ID: 37409251
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The prognostic value of KRAS and BRAF in stage I-III colorectal cancer. A systematic review.
    Gallo G; Sena G; Vescio G; Papandrea M; Sacco R; Trompetto M; Sammarco G
    Ann Ital Chir; 2019; 90():127-137. PubMed ID: 30739887
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RNF43 frameshift mutations contribute to tumourigenesis in right-sided colon cancer.
    Lai C; Sun W; Wang X; Xu X; Li M; Huang D; Xu E; Lai M; Zhang H
    Pathol Res Pract; 2019 Aug; 215(8):152453. PubMed ID: 31122752
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Association Between Mutations in BRAF and Colorectal Cancer-Specific Survival Depends on Microsatellite Status and Tumor Stage.
    Bläker H; Alwers E; Arnold A; Herpel E; Tagscherer KE; Roth W; Jansen L; Walter V; Kloor M; Chang-Claude J; Brenner H; Hoffmeister M
    Clin Gastroenterol Hepatol; 2019 Feb; 17(3):455-462.e6. PubMed ID: 29660527
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRAF
    Trivieri N; Pracella R; Cariglia MG; Panebianco C; Parrella P; Visioli A; Giani F; Soriano AA; Barile C; Canistro G; Latiano TP; Dimitri L; Bazzocchi F; Cassano D; Vescovi AL; Pazienza V; Binda E
    J Exp Clin Cancer Res; 2020 Dec; 39(1):285. PubMed ID: 33317591
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advances in the therapy of BRAF
    Jin Z; Sinicrope FA
    Expert Rev Anticancer Ther; 2019 Sep; 19(9):823-829. PubMed ID: 31455117
    [No Abstract]   [Full Text] [Related]  

  • 29. BRAF-V600E and microsatellite instability prediction through CA-19-9/CEA ratio in patients with colorectal cancer.
    Kasi PM; Kamatham S; Shahjehan F; Li Z; Johnson PW; Merchea A; Colibaseanu DT
    J Gastrointest Oncol; 2020 Apr; 11(2):236-241. PubMed ID: 32399264
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of heavy metals in the development of colorectal cancer.
    Li Y; Lou J; Hong S; Hou D; Lv Y; Guo Z; Wang K; Xu Y; Zhai Y; Liu H
    BMC Cancer; 2023 Jul; 23(1):616. PubMed ID: 37400750
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer.
    Loughrey MB; Waring PM; Tan A; Trivett M; Kovalenko S; Beshay V; Young MA; McArthur G; Boussioutas A; Dobrovic A
    Fam Cancer; 2007; 6(3):301-10. PubMed ID: 17453358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases.
    Fujiyoshi K; Yamamoto G; Takahashi A; Arai Y; Yamada M; Kakuta M; Yamaguchi K; Akagi Y; Nishimura Y; Sakamoto H; Akagi K
    Oncol Rep; 2017 Feb; 37(2):785-792. PubMed ID: 28000889
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers.
    de Cuba EM; Snaebjornsson P; Heideman DA; van Grieken NC; Bosch LJ; Fijneman RJ; Belt E; Bril H; Stockmann HB; Hooijberg E; Punt CJ; Koopman M; Nagtegaal ID; Coupé VH; Carvalho B; Meijer GA
    Int J Cancer; 2016 Mar; 138(5):1139-45. PubMed ID: 26376292
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients.
    Won DD; Lee JI; Lee IK; Oh ST; Jung ES; Lee SH
    BMC Cancer; 2017 Jun; 17(1):403. PubMed ID: 28583095
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mucin phenotype and genetic alterations in non-V600E BRAF-mutated colorectal cancer.
    Ozeki H; Shimada Y; Nakano M; Kondo S; Ohashi R; Miwa Y; Yamai D; Matsumoto A; Abe K; Tajima Y; Ichikawa H; Sakata J; Takii Y; Sugai M; Nagai T; Ling Y; Okuda S; Wakai T
    Hum Pathol; 2024 Mar; 145():71-79. PubMed ID: 38423222
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BRAF V600E mutation in metastatic colorectal cancer: Methods of detection and correlation with clinical and pathologic features.
    Roma C; Rachiglio AM; Pasquale R; Fenizia F; Iannaccone A; Tatangelo F; Antinolfi G; Parrella P; Graziano P; Sabatino L; Colantuoni V; Botti G; Maiello E; Normanno N
    Cancer Biol Ther; 2016 Aug; 17(8):840-8. PubMed ID: 27261210
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Deficient DNA mismatch repair is associated with favorable prognosis in Thai patients with sporadic colorectal cancer.
    Korphaisarn K; Pongpaibul A; Limwongse C; Roothumnong E; Klaisuban W; Nimmannit A; Jinawath A; Akewanlop C
    World J Gastroenterol; 2015 Jan; 21(3):926-34. PubMed ID: 25624727
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical and molecular characteristics of
    Huang ZY; Wen L; Ye LF; Lu YT; Pat Fong W; Zhang RJ; Wu SX; Chen ZG; Cai YY; Xu RH; Li YH; Du ZM; Wang DS
    Ther Adv Med Oncol; 2024; 16():17588359231220600. PubMed ID: 38205077
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation.
    Tie J; Gibbs P; Lipton L; Christie M; Jorissen RN; Burgess AW; Croxford M; Jones I; Langland R; Kosmider S; McKay D; Bollag G; Nolop K; Sieber OM; Desai J
    Int J Cancer; 2011 May; 128(9):2075-84. PubMed ID: 20635392
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations.
    Preto A; Figueiredo J; Velho S; Ribeiro AS; Soares P; Oliveira C; Seruca R
    J Pathol; 2008 Feb; 214(3):320-7. PubMed ID: 18098337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.